Cannabis Use Disorder Market Size, Trends, and Growth Forecast 2025-2032
The Cannabis Use Disorder industry is witnessing a dynamic phase driven by growing awareness, evolving treatment options, and shifting regulatory frameworks. This market's complex landscape is shaped by continuous research advancements and increased adoption of novel therapies. Comprehensive market analysis highlights significant opportunities emerging due to rising cannabis consumption and the consequent demand for effective intervention strategies.
Market Size and Overview
The cannabis use disorder market is estimated to be valued at USD 1.80 Bn in 2025 and is expected to reach USD 3.40 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2032.
This Cannabis Use Disorder Market growth is attributed to expanding research initiatives and increased healthcare focus on behavioral disorders associated with cannabis misuse. Emerging economies are progressively contributing to the market revenue, supported by progressive policy reforms and growing clinical studies emphasizing cannabis dependency treatments.
Market Segments
The Cannabis Use Disorder market is broadly categorized into:
- Treatment Type: Including pharmacological therapies, psychotherapy, and behavioral interventions. Pharmacological treatment holds the dominant share, with novel drug formulations introduced by key manufacturers in 2024 demonstrating accelerated market adoption.
- End User: Hospitals, rehabilitation centers, and outpatient clinics. Hospitals remain the largest revenue generators, while outpatient clinics are the fastest-growing segment due to increasing accessibility and cost-effectiveness.
- Geographical Region: North America, Europe, Asia Pacific, and others. North America continues to lead with high market penetration, and Asia Pacific exhibits rapid expansion, driven by rising diagnostic infrastructure and favorable health policies.
Among these, pharmacological therapies dominate due to breakthroughs such as selective cannabinoid receptor modulators launched in 2025, while outpatient clinics show the fastest CAGR, benefitting from telehealth adoption and regulatory support.
Market Drivers
A key market driver includes the rising prevalence of cannabis use disorder, supported by 2024 epidemiological data indicating a 12% increase in cannabis dependence cases globally. Additionally, government initiatives enhancing funding for mental health and substance abuse treatment programs have propelled market growth. Notably, advancements in personalized medicine approaches, combining pharmacotherapy with behavioral therapy, have increased treatment efficacy and acceptance, creating lucrative market opportunities.
Segment Analysis
Focusing on the Treatment Type segment, pharmacological therapies account for the majority of the market revenue. In 2025, innovative drug candidates addressing withdrawal symptoms and craving reduction have gained regulatory approvals, accelerating uptake. For instance, medications targeting the endocannabinoid system by companies such as Corbus Pharmaceuticals have led to improved patient outcomes. Conversely, psychotherapy, especially cognitive-behavioral therapy integrated with digital tools, has emerged as the fastest-growing sub-segment, reflecting increasing digital health integration.
Consumer Behaviour Insights
End user decision-making patterns in 2024–2025 highlight several shifts:
1. Preference for Personalized Treatment: Surveys show 68% of patients recommend therapies tailored to individual usage patterns and genetic profiles, driving demand for customized pharmacological and combined therapy solutions.
2. Rising Digital Health Adoption: Telehealth platforms for cannabis use disorder management grew by 35% in 2025, reflecting users' preference for remote care due to convenience and privacy concerns.
3. Increased Sensitivity Toward Treatment Costs: Pricing sensitivity has heightened, particularly in emerging markets, prompting companies to develop budget-friendly treatment regimens without compromising clinical efficacy.
Key Players
Prominent market companies driving the Cannabis Use Disorder market include Aelis Farma, Indivior, Pfizer, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals among others.
Throughout 2024 and 2025, these market players advanced their portfolios with new drug launches and expanded manufacturing capacities. For instance, Pfizer introduced a new cannabinoid receptor modulator in 2025 that demonstrated a 20% better success rate in clinical trials, while Indivior expanded its outpatient clinic networks to increase accessibility.
Key Winning Strategies Adopted by Key Players
Innovative market growth strategies by top companies provide critical lessons:
- Aelis Farma (2025): Adopted a biomarker-driven drug development strategy, integrating patient genetic profiling to enhance treatment response rates, boosting clinical trial success and market acceptance.
- Indivior (2024): Implemented a direct-to-consumer education campaign utilizing digital platforms to increase patient enrollment in treatment programs, resulting in a 25% rise in user engagement.
- Corbus Pharmaceuticals (2025): Expanded strategic partnerships with telehealth providers to deliver combined pharmacotherapy and remote counselling services, significantly improving treatment adherence and patient outcomes.
FAQs
1. Who are the dominant players in the Cannabis Use Disorder market?
Key market players include Aelis Farma, Indivior, Pfizer, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals, who have led innovation through product launches and expanded service scopes in 2024 and 2025.
2. What will be the size of the Cannabis Use Disorder market in the coming years?
The market size is forecasted to grow from USD 1.80 billion in 2025 to USD 3.40 billion by 2032, reflecting a CAGR of 9.5%.
3. Which end-user category offers the largest growth opportunity?
Outpatient clinics represent the fastest-growing segment due to increased digital health services and affordable care options.
4. How will market development trends evolve over the next five years?
Market trends point toward integration of personalized medicine, telehealth delivery models, and combination treatment approaches as major growth drivers.
5. What is the nature of the competitive landscape and challenges in the Cannabis Use Disorder market?
The landscape is competitive with innovation-driven market players focusing on regulatory approval and patient-centric treatments. Major challenges include pricing pressures and regulatory variations across regions.
6. What go-to-market strategies are commonly adopted in the Cannabis Use Disorder market?
Leading companies utilize precision medicine development, digital education campaigns, and strategic partnerships with telehealth providers to capture market opportunities.
‣ Get more insights on : Cannabis Use Disorder Market
‣ Get this Report in Japanese Language: 大麻使用障害市場
‣ Get this Report in Korean Language: 대마사용장애시장
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )
